WallStSmart

20/20 Biolabs, Inc. Common Stock (AIDX)vsBoston Scientific Corp (BSX)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 1032642% more annual revenue ($21.07B vs $2.04M). BSX leads profitability with a 16.6% profit margin vs -285.0%. BSX earns a higher WallStSmart Score of 60/100 (C+).

AIDX

Hold

36

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 5.0Quality: 6.0
Piotroski: 4/9Altman Z: -13.90

BSX

Buy

60

out of 100

Grade: C+

Growth: 4.7Profit: 7.0Value: 6.0Quality: 6.0
Piotroski: 5/9Altman Z: 1.78
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for AIDX.

BSXOvervalued (-13.3%)

Margin of Safety

-13.3%

Fair Value

$39.14

Current Price

$43.70

$4.56 premium

UndervaluedFair: $39.14Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AIDX3 strengths · Avg: 9.0/10
Revenue GrowthGrowth
36.5%10/10

Revenue surging 36.5% year-over-year

Debt/EquityHealth
0.189/10

Conservative balance sheet, low leverage

Price/BookValuation
1.6x8/10

Reasonable price relative to book value

BSX3 strengths · Avg: 8.3/10
Market CapQuality
$64.07B9/10

Large-cap with strong market position

PEG RatioValuation
0.768/10

Growing faster than its price suggests

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Areas to Watch

AIDX4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$2.62M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-354.6%2/10

ROE of -354.6% — below average capital efficiency

Free Cash FlowQuality
$-610,8142/10

Negative free cash flow — burning cash

BSX3 concerns · Avg: 3.3/10
Revenue GrowthGrowth
1.4%4/10

1.4% revenue growth

Altman Z-ScoreHealth
1.784/10

Distress zone — elevated risk

EPS GrowthGrowth
-21.5%2/10

Earnings declined 21.5%

Comparative Analysis Report

WallStSmart Research

Bull Case : AIDX

The strongest argument for AIDX centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 36.5% demonstrates continued momentum.

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, Price/Book. Profitability is solid with margins at 16.6% and operating margin at 19.6%. PEG of 0.76 suggests the stock is reasonably priced for its growth.

Bear Case : AIDX

The primary concerns for AIDX are EPS Growth, Market Cap, Return on Equity.

Bear Case : BSX

The primary concerns for BSX are Revenue Growth, Altman Z-Score, EPS Growth.

Key Dynamics to Monitor

AIDX profiles as a hypergrowth stock while BSX is a value play — different risk/reward profiles.

BSX carries more volatility with a beta of 0.58 — expect wider price swings.

AIDX is growing revenue faster at 36.5% — sustainability is the question.

BSX generates stronger free cash flow (868M), providing more financial flexibility.

Bottom Line

BSX scores higher overall (60/100 vs 36/100), backed by strong 16.6% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

20/20 Biolabs, Inc. Common Stock

HEALTHCARE · MEDICAL DEVICES · USA

20/20 Biolabs, Inc. (AIDX) is a pioneering biotechnology company dedicated to advancing genomic research and diagnostics through its cutting-edge laboratory services. Focused on improving the accuracy and efficiency of genetic testing for both clinical and research applications, the company is set to establish itself as a leader in the molecular diagnostics market. With a strategic emphasis on personalized medicine and a robust portfolio of state-of-the-art technologies, 20/20 Biolabs is well-positioned to meet the surging demand for genomic data and capitalize on emerging opportunities within the dynamic biotechnology landscape. Its innovative approach and strong market presence reflect a promising growth trajectory in an industry characterized by rapid advancements.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Want to dig deeper into these stocks?